Source:http://linkedlifedata.com/resource/pubmed/id/11239170
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2001-3-12
|
| pubmed:abstractText |
In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy. We compared the progression-free survival (PFS) and overall survival (OS) of 20 patients treated with a double (D)-HDCT regimen to 20 patients who received a triple (T)-HDCT, matched by age, estrogen receptor (ER) status, adjuvant chemotherapy, initial disease-free interval, predominant metastatic site, and number of metastatic sites. At a median follow-up of 41.5 months (range, 14-88 months) an intent-to-treat analysis showed no difference in PFS (p = 0.72) and OS (p = 0.93) between the matched patients. For all 76 patients treated within the D- or T-HDCT trial, median PFS and OS was 13 months (range, 2-78 months) and 24.5 months (range, 7-78 months), respectively. In multivariate analysis independent predictors of shorter OS included negative ER (relative risk [RR] = 3.0 [95% confidence interval (CI) 1.5-5.9]; p = 0.002), more than two metastatic sites (RR = 2.4 [95% CI 1.0-5.7]; p = 0.049) and failure to achieve complete remission/no evidence of disease (CR/NED) after HDCT (RR = 4.5 [95% CI 2.0-10.1]; p < 0.0001). These data show that early dose intensification with T-HDCT is not superior to a D-HDCT regimen in patients with MBC. ER-negative tumors, more than two metastatic sites and no CR/NED after HDCT, are associated with inferior outcome.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Thiotepa
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1066-5099
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
151-60
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11239170-Adult,
pubmed-meshheading:11239170-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11239170-Breast Neoplasms,
pubmed-meshheading:11239170-Carboplatin,
pubmed-meshheading:11239170-Dose-Response Relationship, Drug,
pubmed-meshheading:11239170-Epirubicin,
pubmed-meshheading:11239170-Female,
pubmed-meshheading:11239170-Follow-Up Studies,
pubmed-meshheading:11239170-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11239170-Hematopoietic Stem Cells,
pubmed-meshheading:11239170-Humans,
pubmed-meshheading:11239170-Ifosfamide,
pubmed-meshheading:11239170-Liver Neoplasms,
pubmed-meshheading:11239170-Middle Aged,
pubmed-meshheading:11239170-Paclitaxel,
pubmed-meshheading:11239170-Soft Tissue Neoplasms,
pubmed-meshheading:11239170-Thiotepa,
pubmed-meshheading:11239170-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
|
| pubmed:affiliation |
Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. andreas_schneeweiss@med.uni-heidelberg.de
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|